Inizio strengths senior team with DE&I appointment

International strategic health and life science specialists Inizio have increased their organizational-wide focus on diversity, equity, and inclusion with the appointment of Stefanie Christmas as their new Global Head of Diversity, Equity & Inclusion (DE&I).

BioIVT to Highlight its Drug-Drug Interaction and ADME Research Expertise at the SOT Annual Meeting and ToxExpo

It will provide strategies to de-risk each stage of the R&D pipeline, with particular focus on regulatory drivers, investigatory objectives, and practical concerns that are relevant to toxicologists.

Recipharm's Arranta Bio expands RNA process development capacity by 50 percent to meet increased customer demand

Arranta Bio, a Recipharm company and leading contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers, has announced that it has doubled capacity at its Watertown, MA facility for process development services supporting RNA therapeutics.

Mural Health and ProofPilot Partner to Streamline Payments and Provide More Patient Choice

Mural Health, a clinical trials technology company that improves the patient and caregiver experience in order to improve enrollment rates, participant retention, and increase protocol compliance and ProofPilot, the industry's first digital protocol automation platform for clinical trial, today announced a strategic partnership to further advance clinical trial operations for life science customers. Through this partnership, Mural Health’s Mural Link™ platform and ProofPilot’s platform work together to progress clinical operations and materially improve the efficiency, and outcomes, of global clinical trials.

Implanting a Better Future: Navigating the Changing Dynamics of the Medical Implant Industry

The COVID-19 pandemic has had a major impact on the implant industry, both positively and negatively. Here are some of the main effects:

New study shows low endotoxin biomaterials improve reliability of 3D in vitro models; Pave the way for reduced animal testing

Darling Ingredients’ health brand Rousselot, the global leader1 in collagen-based solutions, announced today that a new study has found that utilization of highly purified gelatin biomaterials for 3D in vitro models can significantly enhance the reliability and reproducibility in these models, creating new possibilities for replacing preclinical animal trials.

Clinion Launches Revolutionary AI-Powered Medical Coding Solution for Clinical Trials

[London, UK] - Clinion, a leading provider of eClinical solutions, has announced the launch of its new AI-powered medical coding solution. This innovative solution is designed to transform the medical coding process for clinical trials, offering a faster, more efficient, and more accurate way to code medical data. Medical coding is a critical component of clinical trials, as it enables researchers to accurately capture and analyze medical data. However, the process of medical coding can be time-consuming, error-prone, and costly, often leading to delays in the clinical trial process. Clinion's new AI Medical Coding is set to revolutionize the clinical trial process by leveraging the power of artificial intelligence to automate medical coding. The solution uses advanced machine learning algorithms to analyze medical data and assign the appropriate medical codes, significantly reducing the time and effort required for manual coding. The solution also provides real-time feedback to clinical trial teams, allowing them to make data-driven decisions more quickly and efficiently. With improved accuracy and speed, Clinion's medical coding solution enables clinical trial teams to deliver high-quality results and insights faster than ever before. "We are thrilled to launch AI Medical Coding, which we believe will transform the clinical trial process," said Manuj Vangipurapu, CEO of Clinion. "By harnessing the power of AI, we can provide clinical trial teams with a faster, more efficient, and more accurate way to code medical data. This will enable our customers to make data-driven decisions more quickly and effectively, ultimately accelerating the drug development process and bringing new treatments to patients faster." Clinion's medical coding solution is the latest addition to its suite of eClinical solutions, which include EDC, RTSM, ePRO, eConsent and CTMS. sWith over 500+ clinical trials successfully conducted using its solutions, Clinion is the go-to partner for companies seeking to streamline their clinical trial process and bring new treatments to market faster. For more information on Clinion's new AI-powered medical coding solution, please visit clinion.com. About Clinion Clinion is a global clinical technology company that offers AI-enabled eClinical solutions consisting of EDC, RTSM, CTMS, eCOA and Document Automation that cover the entire clinical trial lifecycle. Clinion is committed to innovating the future of clinical trials through AI/ML and empowering its partners to manage trials more efficiently at lesser costs. For more information, please visit www.clinion.com.

Clinical Trial Technology Trends: The Top 5 Innovations Shaping Clinical Trials in 2023

Discover the top 5 clinical trial technology trends in 2023. From wearables to AI, Digital Patient engagement tools and techniques that are shaping the future of clinical research

Orbita and Isabel Healthcare improve provider websites, patient experience

Orbita, a provider of virtual assistants for healthcare, announced a partnership with Isabel Healthcare that will improve patients’ digital experiences, helping them find the right care for their individual health circumstances.

ARIA MARKETING AND ESCALATE PR PARTNER TO BRING THE MOST COMPREHENSIVE MARKETING OFFERING TO TECH AND HEALTHCARE

Confluence of Industries Requires Nimble, Creative, and Cross-functional Expertise that Flexes and Scales For Pure-play and Multi-line Businesses

Optical Brighteners, Plasticizers, and Antioxidants as Polymer Stabilizers

Biopharma PEG To Attend PEGS Boston Summit 2023

Huateng Pharma Announced To Present CPhI North America In April 2023

NCC Group Appoints New Global Capability Leader for Managed Services to Drive Next Chapter of Strategy

NCC Group – one of the world’s largest and most respected security consultancies with over 35 global offices, 2,000 employees and 14,000 clients – today appointed Doug Klotnia as global capability leader for Managed Services.

Life sciences lab automation provider Automata expands into the United States

Automata, a leader in open, integrated laboratory automation, announces its expansion into the US. Automata is accelerating scientific and health outcomes by making automation a reality for every lab.

Thermo Fisher Scientific Simplifies Trace Elemental Analysis in Environmental, Food, Pharmaceutical and Industrial Testing Labs

Today, Thermo Fisher Scientific launched an easy-to-use solution for the analysis of trace elements in environmental, food, and pharmaceutical laboratories. The Thermo Scientific iCAP RQplus ICP-MS Analyzer provides the operational simplicity and stability that laboratories require for ongoing daily analysis of trace elements at low concentrations in a wide range of sample types. The company also announced the Thermo Scientific iSC-65 Autosampler which enhances the productivity of the Thermo Scientific iCAP Qnova Series ICP-MS analyzer and the Thermo Scientific iCAP PRO Series ICP-OES.

New Micropep Executive Appointment Signals Drive to AgTech Product Commercialization

Micropep Technologies appoints Alexandre Frateschi as chief business officer, signaling drive to agTech product commercialization.

Thermo Fisher Scientific Introduces New Low-Flow HPLC Columns for Proteomic Research

PRODUCT BRIEF – March 7, 2023 Thermo Fisher Scientific Introduces New Low-Flow HPLC Columns for Proteomic Research Thermo Scientific µPAC Neo HPLC Columns Deliver Improved Separation Performance and Stability for Biologically Complex Samples News: Thermo Fisher Scientific is providing proteomics and biopharmaceutical research laboratories with a new line of low-flow HPLC columns that improve separation performance and stability of biologically complex samples. Overview: Using a unique micro-pillar separation structure, the Thermo Scientific µPAC Neo HPLC Columns enable researchers to investigate proteomics samples in greater detail, from accurate identification of peptides to determination of protein quantities, discovery of disease biomarkers and post-translational modifications. The newest addition to the portfolio is the µPAC Neo low-load trapping column which is ideally suited for the smallest samples sizes in single-cell proteomics separations and features built-in nanoViper connections to the Vanquish Neo UHPLC systems for ease of use and reduced risk of errors. Users of all µPAC Neo columns benefit from excellent column reproducibility, allowing for more reliable data interpretation and confidence in their results. The full µPAC Neo column portfolio offers: • 50 cm µPAC Neo column for routine proteomics • 110 cm µPAC Neo column for comprehensive proteomics • 50 cm µPAC Neo low-load column for single-cell proteomics • µPAC Neo low-load trapping column to support single-cell proteomics separations µPAC Neo columns are manufactured by micromachined etching of silicon wafers, resulting in highly reproducible separation paths. For proteomics researchers, this provides higher column-to-column consistency and longer column lifetimes compared to packed-bed columns, allowing for more robust development and validation of methods and easier study of larger sample batches. Key Applications: Proteomics and biopharmaceutical research Features/Benefits: • Unique column technology that delivers optimal sample coverage and improved protein identification • Extra-high resolution separations of highest complexity samples • Excellent column reproducibility for more reliable data interpretation • Long column lifetimes to reduce the number of column exchanges and increase system uptime Website: To learn more about the new µPAC Neo HPLC Columns, please visit www.thermofisher.com/lowflowHPLCcolumns. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Curebase Selected Among Y Combinator’s Top Private Companies of 2023

DCT platform company places in top 6% of private companies; recognized for end-to-end clinical trial execution built on cutting-edge software

CD ComputaBio Introduces AutoDock, a Powerful Molecular Docking Software